Patent · US Active

Very low-dosed solid oral dosage forms for HRT

US9592245B2 · kind B2 · utility

0Cited by

4References

10Claims

0Family size

Assignee

Bayer Intellectual Property GmbH · DE

Inventors

Stephan Mletzko · Berlin, DE
Rolf Schürmann · Teltow, DE
Kerstin Gude · Birkenwerder, DE

Key dates

Filing date	Dec 8, 2014
Grant date	Mar 14, 2017
Priority date	—
Expiry date	Dec 8, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.